GlassScriptPhysician profile
Susan Adams
NPI 1871584474
$2,720.12
in general payments reported to CMS, 2019-2025
36 companies · $577 in 2025
The $577 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $246 · 2021: $13.38 · 2022: $131 · 2023: $166 · 2024: $326 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322.06 | 2019-2025 | Wegovy, Sogroya |
| Pfizer INC. | $249.32 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.96 | 2019-2022 | |
| Lilly USA, LLC | $208.11 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $177.16 | 2023-2025 | Skytrofa |
| Abbvie INC. | $153.88 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $130.97 | 2019-2023 | Bexsero, Shingrix, Arexvy |
| Astellas Pharma US INC | $129.96 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $125.88 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $123.64 | 2024-2025 | Austedo Xr, Austedo Xr |
| Azurity Pharmaceuticals, INC. | $95.14 | 2024-2025 | Triptodur |
| Amarin Pharma, INC. | $71.41 | 2019-2020 | |
| Dexcom, INC. | $62.02 | 2020-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $60.96 | 2019 | |
| Neurelis, INC. | $54.73 | 2023-2025 | Valtoco |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.69 | 2019-2020 | |
| Tris Pharma INC | $45.31 | 2019-2023 | Dyanavel Xr |
| Amphastar Pharmaceuticals, INC. | $40.38 | 2024-2025 | |
| Sanofi Pasteur INC. | $32.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $30.78 | 2024-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Amgen INC. | $29.87 | 2019 | |
| Neurocrine Biosciences, INC. | $29.35 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.02 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.86 | 2019 | |
| Ironshore Pharmaceuticals INC. | $23.79 | 2024 | |
| Tandem Diabetes Care, INC. | $20.80 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corium, LLC | $20.20 | 2023 | Azstarys |
| Allergan, INC. | $17.86 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.79 | 2019 | |
| Noven Therapeutics, LLC | $16.64 | 2024 | Xelstrym |
| Sandoz INC. | $16.45 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.35 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.81 | 2025 | Relexxii |
| Shire North American Group INC | $13.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.86 | 2019 | |
| Kaleo, INC. | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.